Acorai: Difference between revisions
Added new company |
Added valuation: ~€20-40M (€4.2M+ raised) |
||
| Line 12: | Line 12: | ||
== Funding == | == Funding == | ||
'''Valuation:''' ~€20-40M (€4.2M+ raised) | |||
* €2.3M seed round<ref>MassDevice (2023): "Intracardiac pressure monitoring device startup Acorai raises €2.3M"</ref> | * €2.3M seed round<ref>MassDevice (2023): "Intracardiac pressure monitoring device startup Acorai raises €2.3M"</ref> | ||
* €4.2M additional (December 2024), preparing to raise additional capital<ref>Silicon Canals (Dec 2024): "Sweden's Acorai bags €4.2M to advance its heart failure management devices"</ref> | * €4.2M additional (December 2024), preparing to raise additional capital<ref>Silicon Canals (Dec 2024): "Sweden's Acorai bags €4.2M to advance its heart failure management devices"</ref> | ||
Revision as of 07:42, 14 April 2026
What They Do
Non-invasive intracardiac pressure monitor for heart failure management. The device measures pressure inside the heart without invasive catheterization, enabling continuous monitoring of heart failure patients.[1]
Funding
Valuation: ~€20-40M (€4.2M+ raised)
Regulatory
Received FDA Breakthrough Device Designation for their non-invasive intracardiac pressure monitor.[4] This designation accelerates the FDA review process for devices addressing unmet medical needs.
See Also
- ↑ TechCrunch (2023): "Heart failure monitoring startup Acorai turns heads with oversubscribed seed"
- ↑ MassDevice (2023): "Intracardiac pressure monitoring device startup Acorai raises €2.3M"
- ↑ Silicon Canals (Dec 2024): "Sweden's Acorai bags €4.2M to advance its heart failure management devices"
- ↑ PR Newswire (2024): "Acorai receives Breakthrough Device Designation for their non-invasive intracardiac pressure monitor"